Halberd’s patented process demonstrates eradication of multiple strains of antibiotic resistant bacteria and fungi in under 10 minutes.
Jackson Center, PA, March 14, 2023 – Halberd Corporation (OTC PINK:HALB) is scheduled to meet with Center of Disease Control (CDC) representatives to discuss Halberd’s incredible success in eradicating multiple strains of antibiotic resistant (AR) E. coli bacteria and Candida auris samples previously provided by the CDC. The testing, currently underway at Youngstown State University (YSU) using Halberd’s patented extracorporeal laser eradication process, eradicated over 90% of the AR bacteria and AR fungus, in vitro in under 10 minutes compared to up to 10 days using oral or injected antibiotics (the current standard of care).
Dr. Cooper, Professor, Department of Chemical and Biological Sciences at YSU, and Halberd’s primary interface with the CDC, stated, “We are anxious to report our progress to the CDC in our meeting on March 29th.”
Dr. Sturrus, Chair and Professor, Physics, Astronomy Geology and Environmental Science Department at YSU added, “To date, using Halberd’s patented technology process, we have been successful in our in vitro laboratory tests in eradicating inflammatory cytokines associated with neurodegenerative diseases, excitatory neuro transmitters (Glutamate) associated with head trauma, antibiotic-resistant bacteria and Candida auris in 10 minutes or less of laser irradiation. This is truly a breakthrough technology worthy of support by the scientific community.”
William A. Hartman, Halberd’s Chairman, President & CEO commented, “This meeting with the CDC is a tremendous opportunity for Halberd to present our incredible results to the antibiotic resistant bacteria experts at the CDC. To date, we have been able to demonstrate eradication of 12 of the 18 strains of antibiotic resistant E. coli provided by the CDC within just 10 minutes or less of laser emissive energy exposure using our patented process, and we are on track to have the remainder of the 18 strains of bacteria tested prior to our meeting with the CDC on March 29th. We have also had preliminary success with 4 of the 20 strains of candida auris provided by the CDC and will begin testing our method on the 12 strains of Klebsiella pneumoniae from the CDC.”
Hartman concluded, “We will continue to contact other government agencies as well as potential partners in order to expedite the further development of our patented technology.”
To get the latest news on Halberd’s exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
For more information please contact:
William A. Hartman
About Youngstown State University
Youngstown State University is a public university in Youngstown, Ohio, and is composed of 5 undergraduate colleges. The University has over 150 undergraduate degree programs and 50 graduate degree programs serving over 12,000 students in studies up to the doctoral level. Beyond its current student body, the university has more than 125,000 alumni across the country and around the world.
About Halberd Corporation.
Halberd Corporation (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to four issued patents and has filed twenty related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Company cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Company undertakes no obligation to revise these statements following the date of this news release.